

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/19979> holds various files of this Leiden University dissertation.

**Author:** Buckle, Tessa

**Title:** Interventional molecular imaging, a hybrid approach

**Date:** 2012-10-17

# **Interventional molecular imaging, a hybrid approach**

**List of publications**

---

- 1 Kuil J, **Buckle T**, van Leeuwen FWB. Imaging agents for the chemokine receptor 4 (CXCR4). *Chem Soc Rev.* 2012 7; 41(15): 5239-5261
- 2 **Buckle T**, Brouwer OR, Valdés-Olmos RA, van der Poel HG, van Leeuwen FWB. Relation between intraprostatic tracer deposits and sentinel lymph node mapping in prostate cancer patients. *J Nucl Med.* 2012; 53: 1026-1033
- 3 Brouwer OR, **Buckle T**, Vermeeren L, Klop WMC, Balm AJM, van der Poel HG, van Rhijn BW, Horenblas S, Nieweg OE, van Leeuwen FWB, Valdés-Olmos RA. Comparing the Hybrid Fluorescent-Radioactive Tracer Indocyanine Green-99mTc-Nanocolloid with 99mTc-Nanocolloid for Sentinel Node Identification: A Validation Study Using Lymphoscintigraphy and SPECT/CT. *J Nucl Med.* 2012; 53: 1034-1040
- 4 Brouwer OR, **Buckle T**, Bunschoten A, Kuil J, Wendler T, Vahrmeijer AL, Valdés-Olmos RA, van der Poel HG, van Leeuwen FWB. Image navigation as a means to improve the accuracy of fluorescence guided surgery: fine tuning (hybrid) image guided surgery. *Phys Med Biol.* 2012; 57: 3123
- 5 Brouwer OR, Klop MWC, **Buckle T**, van den Brekel MWM, Balm FJM, Nieweg OE, Valdés-Olmos RA, van Leeuwen FWB. Feasibility of sentinel node biopsy in head and neck melanoma using a hybrid radioactive and fluorescent tracer. *Ann Surg Oncol.* 2012; 19(6): 1988-1994
- 6 Bunschoten A#, **Buckle T**#, Visser N, Yuan H, Josephson L, Vahrmeijer AL, van Leeuwen FWB. Multimodal interventional molecular imaging of tumor margins and distant metastases using the  $\alpha_v\beta_3$ -integrin expression. *ChemBioChem.* 2012; 13(7): 1039-1045 (# authors contributed equally)
- 7 **Buckle T**, van den Berg NS, Kuil J, Bunschoten A, Oldenburg J, Borowsky AD, Wesseling J, Masada R, Oishi S, Fujii N, van Leeuwen FWB. In vivo imaging of CXCR4 in breast cancer using an  $^{111}\text{In}$  labeled peptide antagonist. *Am J Nucl Med Mol Imaging.* 2012; 2(1): 99-109
- 8 Steunenbergh P, Ruggi A, van den Berg NS, Kuil J, **Buckle T**, van Leeuwen FWB, Velders AH. Synthesis, cellular uptake and localization of luminescent amino-acid functionalized tris(phenylpyridine)iridium(III) complexes. *Inorg Chem.* 2012; 51: 2105-2114
- 9 Chin PTK, Beekman CA, **Buckle T**, Josephson L, van Leeuwen FWB. Multispectral visualization of surgical safety-margins using multimodal marker seeds. *Am J Nucl Med Mol Imaging.* 2012; 2(2): 151-162

- 10 Bunschoten A, **Buckle T**, Kuil J, Luker GD, Luker KE, Nieweg OE, van Leeuwen FWB. Targeted non-covalent self-assembled nanoparticles based on human serum albumin. *Biomaterials*. 2012; 33(3): 867-875
- 11 de Vries NA, **Buckle T**, Zhao J, Beijnen JH, Schellens JH, van Tellingen O. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. *Invest New Drugs*. 2012; 30(2): 443-449
- 12 van der Poel HG, Brouwer OR, van den Berg NS, **Buckle T**, van Leeuwen FWB. Reply to K. Polom, D. Murawa, W. Polom's Letter to the Editor re: Henk G. van der Poel, Tessa Buckle, Oscar R. Brouwer, Renato A. Valdés-Olmos, Fijs W.B. van Leeuwen. Intraoperative Laparoscopic Fluorescence Guidance to the Sentinel Lymph Node in Prostate Cancer Patients: Clinical Proof of Concept of an Integrated Functional Imaging Approach Using a Multimodal Tracer. *Eur Urol*. 2011; 60: 826-833
- 13 Kuil J, **Buckle T**, Oldenburg J, Yuan H, Borowsky AD, Josephson L, van Leeuwen FWB. Hybrid Peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression. *Mol Pharm*. 2011; 8(6): 2444-2453
- 14 van den Berg NS#, **Buckle T**#, Kuil J, Wesseling J, van Leeuwen FWB. Immunohistochemical detection of the CXCR4 expression in tumor tissue using the fluorescent peptide antagonist Ac-TZ14011-FITC. *Transl Oncol*. 2011; 4(4): 234-240 (#authors contributed equally)
- 15 Kuil J#, **Buckle T**#, Yuan H, van den Berg NS, Oishi S, Fujii N, Josephson L, van Leeuwen FWB. Synthesis and evaluation of a bimodal CXCR4 antagonistic peptide. *Bioconjug Chem*. 2011; 22(5): 859-864. (# authors contributed equally)
- 16 van der Poel HG, **Buckle T**, Brouwer OR, Valdés Olmos RA, van Leeuwen FWB. Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. *Eur Urol*. 2011; 60(4): 826-833
- 17 van Leeuwen AC#, **Buckle T**#, Bendle G, Vermeeren L, Valdés-Olmos RA, van de Poel HG, van Leeuwen FWB. Tracer-cocktail injections for combined pre- and intraoperative multimodal imaging of lymph nodes in a spontaneous mouse prostate tumor model. *J Biomed Opt*. 2011; 16(1): 016004. (# authors contributed equally)
- 18 Beekman CAC#, **Buckle T**#, van Leeuwen AC, Valdés-Olmos RA, Verheij M, Rottenberg S, van Leeuwen FWB. Questioning the value of (99m)Tc-HYNIC-annexin V based response monitoring after docetaxel treatment in a mouse model for hereditary breast cancer. *Appl Radiat Isot*. 2011; 69(4): 656-62. (# authors contributed equally)

- 19 **Buckle T**, Chin PT, van Leeuwen FWB. (Non-targeted) radioactive/fluorescent nanoparticles and their potential in combined pre- and intraoperative imaging during sentinel lymph node resection. *Nanotechnology*. 2010; 21(48): 482001
- 20 **Buckle T**, Chin PT, van den Berg NS, Loo CE, Koops W, Gilhuijs KG, van Leeuwen FWB. Tumor bracketing and safety margin estimation using multimodal marker seeds: a proof of concept. *J Biomed Opt*. 2010; 15(5): 056021
- 21 **Buckle T**, van Leeuwen AC, Chin PT, Janssen H, Muller SH, Jonkers J, van Leeuwen FWB. A self-assembled multimodal complex for combined pre- and intraoperative imaging of the sentinel lymph node. *Nanotechnology*. 2010; 21(35): 355101
- 22 van Leeuwen FWB, **Buckle T**, Batteau L, Pool B, Sinaasappel M, Jonkers J, Gilhuijs KG. Potential value of color-coded dynamic breast-specific gamma-imaging; comparing (99m)Tc-(V)-DMSA, (99m)Tc-MIBI, and (99m)Tc-HDP in a mouse mammary tumor model. *Appl Radiat Isot*. 2010; 68(12): 2117-2124
- 23 Chin PT, **Buckle T**, Aguirre de Miguel A, Meskers SC, Janssen RA, van Leeuwen FWB. Dual-emissive quantum dots for multispectral intraoperative fluorescence imaging. *Biomaterials*. 2010; 31(26): 6823-6832
- 24 de Vries NA, Bruggeman SW, Hulsman D, de Vries HI, Zevenhoven J, **Buckle T**, Hamans BC, Leenders WP, Beijnen JH, van Lohuizen M, Berns AJ, van Tellingen O. Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies. *Clin Cancer Res*. 2010; 16(13): 3431-3441
- 25 Oostendorp RL, **Buckle T**, Lambert G, Garrigue JS, Beijnen JH, Schellens JH, van Tellingen O. Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice. *Invest New Drugs*. 2011; 29(5): 768-776
- 26 **Buckle T**, van Leeuwen FWB. Validation of intratracheal instillation of lung tumour cells in mice using single photon emission computed tomography/computed tomography imaging. *Lab Anim*. 2010; 44(1): 40-45
- 27 Beumer JH, Franke NE, Tolboom R, **Buckle T**, Rosing H, Lopez-Lazaro L, Schellens JH, Beijnen JH, van Tellingen O. Disposition and toxicity of trabectedin (ET-743) in wild-type and *mdr1* gene (P-gp) knock-out mice. *Invest New Drugs*. 2010; 28(2): 145-155
- 28 van Leeuwen FWB, **Buckle T**, Kersbergen A, Rottenberg S, Gilhuijs KG. Noninvasive functional imaging of P-glycoprotein-mediated doxorubicin resistance in a mouse model of hereditary breast cancer to predict response, and assign P-gp inhibitor sensitivity. *Eur J Nucl Med Mol Imaging*. 2009; 36(3): 406-412

- 
- 29 Niers TM, Brüggemann LW, Klerk CP, Muller FJ, **Buckle T**, Reitsma PH, Richel DJ, Spek CA, Van Tellingen O, Van Noorden CJ. Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung. *Clin Exp Metastasis*. 2009; 26(3): 171-178
  - 30 Marchetti S, de Vries NA, **Buckle T**, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. *Mol Cancer Ther*. 2008; 7(8): 2280-2287
  - 31 Oostendorp RL, **Buckle T**, Beijnen JH, van Tellingen O, Schellens JH. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. *Invest New Drugs*. 2009; 27(1): 31-40
  - 32 de Vries NA, Zhao J, Kroon E, **Buckle T**, Beijnen JH, van Tellingen O. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. *Clin Cancer Res*. 2007; 13(21): 6440-6449
  - 33 Klerk CP, Overmeer RM, Niers TM, Versteeg HH, Richel DJ, **Buckle T**, Van Noorden CJ, van Tellingen O. Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. *Biotechniques*. 2007; 43(1 Suppl): 7-13, 30
  - 34 Bruggeman SW, Hulsman D, Tanger E, **Buckle T**, Blom M, Zevenhoven J, van Tellingen O, van Lohuizen M. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. *Cancer Cell*. 2007; 12(4): 328-341
  - 35 de Vries NA, Ouwehand M, **Buckle T**, Beijnen JH, van Tellingen O. Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography. *Biomed Chromatogr*. 2007; 21(11): 1191-1200
  - 36 Kemper EM, Leenders W, Küsters B, Lyons S, **Buckle T**, Heerschap A, Boogerd W, Beijnen JH, van Tellingen O. Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies. *Eur J Cancer*. 2006; 42(18): 3294-3303
  - 37 Beumer JH, **Buckle T**, Ouwehand M, Franke NE, Lopez-Lazaro L, Schellens JH, Beijnen JH, van Tellingen O. Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. *Invest New Drugs*. 2007; 25(1): 1-7

- 38 Press RR, **Buckle T**, Beijnen JH, van Tellingen O. The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice. *Cancer Chemother Pharmacol.* 2006; 57(6): 819-825
- 39 van Tellingen O, Bardelmeijer HA, **Buckle T**, Ouwehand M, Beijnen JH, Schellens JH. Cannulation of the jugular vein in mice. *Lab Anim.* 2005; 39(1): 130
- 40 van Tellingen O, **Buckle T**, Jonker JW, van der Valk MA, Beijnen JH. P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo. *Br J Cancer.* 2003; 89(9): 1776-1782
- 41 Bardelmeijer HA, **Buckle T**, Ouwehand M, Beijnen JH, Schellens JH, van Tellingen O. Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples. *Lab Anim.* 2003; 37(3): 181-187
- 42 Bardelmeijer HA, Ouwehand M, **Buckle T**, Huisman MT, Schellens JH, Beijnen JH, van Tellingen O. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. *Cancer Res.* 2002; 62(21): 6158-6164





